MD · MBA
Physician specializing in genetic analysis and personalized preventive medicine, and author of Outsmart Your Genes.
Brandon Colby is a physician-expert in the fields of genetic analysis and Personalized Preventive Medicine. He holds an MD from the Mount Sinai School of Medicine, an MBA from Stanford University's Graduate School of Business, and a degree in Genetics from the University of Michigan.
Dr. Colby is the author of the book Outsmart Your Genes and has developed numerous technologies that improve the analysis, interpretation, and actionability of genome sequencing data. He is an Affiliate Specialist of the American College of Medical Genetics and Genomics (ACMG), an Associate of the American College of Preventive Medicine (ACPM), and a member of the National Society of Genetic Counselors (NSGC).
Articles by Brandon Colby, MD are reviewed for accuracy by Sequencing's medical and scientific team. This page is for informational purposes and does not constitute medical advice.
Discover the importance of genetic testing in diagnosing thyroid adenoma and hyperthyroidism, uncovering genetic risk factors, and guiding personalized treatment options.
Discover the role of genetic testing in diagnosing and treating TNF receptor binding alterations, guiding personalized care for autoimmune diseases and cancer.
Discover the benefits of genetic testing for diagnosing Townes-Brocks-Branchiootorenal-Like Syndrome, a rare genetic disorder. Learn about new mutations, treatment guidance, and…
Discover the role of genetic testing in diagnosing transient hyperlipidemia, identifying gene mutations, guiding personalized treatment, and preventing complications.
Discover the role of genetic testing in diagnosing trifascicular block, a complex heart condition, and how it can guide personalized treatment and risk assessment.
Explore Triosephosphate Isomerase Manchester, a rare metabolic disorder, its diagnosis, and the role of genetic testing in managing this complex condition.
Discover the role of genetic testing in diagnosing and managing triple-negative breast cancer, and explore promising novel treatments for this aggressive subtype.